Latest News

Detroit R&D BioTarget® Hypertension ELISA.

Publications on sEH-induced diseases studied using Detroit R&D BioTarget® Hypertension ELISA.

1.  Kim et al. Four US Patents on hypertension: 6,440,682, 6,534,282, 7,695,927 and 8,409,821.

Issue Dates: 8/2002 http://www.freepatentsonline.com/6440682.pdf (Activity)

                       3/2003 http://www.freepatentsonline.com/6534282.pdf (Diagnostics)

                       4/2010 http://www.freepatentsonline.com/7695927.pdf (Diagnostics)

                       4/2013 http://www.freepatentsonline.com/8409821.pdf (Drug screening)

2.  Spiecker et al. Risk of coronary artery disease associated with polymorphism of the cytochrome p450 epoxygenase CYP2J2. Circulation 110, 2132, 2004.

3.  Kim et.al. Computational characterization of a series of eicosanoids. Lett. Drug Design & Discovery 2, 322-325. 2005

4.  Zhang et.al. Effects of atorvastatin on expression of cytochrome P450 epoxygenase 2C11 in spontaneously hypertensive rats.  International Journal of Automation and Computing, 20, 305-311, 2006.

5.  Alkayed, et al. Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury.  The Journal of Neuroscience, 27(17): 4642-4649, April 25, 2007.

6.  Zeldin, et al. Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-a via MAPK and PI3K/Akt signaling pathways.  Am J. Physiol Heart Circ Physiol 293, H142-H151, 2007.

7.  Chen et al. Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Artherosclerosis 195, 199-206. 2007.

8.  Alkayed et al. Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke 39, 2073-2078, 2008.

9.  Alkayed et al.  Role of soluble epoxide hydrolase in the sex-specific vascular response to cerebral ischemia. J. Cerebral Blood Flow & Metabolism 29, 1475-1481. 2009.

10. Eldrup et al. Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.  J. Med. Chem. 52, 5880-5895, 2009.

11. Xu, Zeldin, Wang et al. Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice. Diabetes 59, 997. 2010.

12. Wang et al. Gene delivery of cytochrome P450 epoxygenase ameliorates monocrotaline-induced pulmonary artery hypertension in rats. Am. J. Respir. Cell Mol. Biol. 43, 740-749, 2010.

13. Wang et al. Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide. J. Pharmaol. Exp. Ther. 334, 784-794, 2010.

14. Van Winkle et al. Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: Role of STAT3 signaling. Am. J. Physiol. Heart Circ.  Physiol. 298: H679-H687, 2010.

15. Cervenka, Kramer, Falck, Imig, Hammock et al. Combined inhibition of 20-HETE  formation and of EET degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clinical Science 118, 617-632. 2010.

16. Cervenka, Kramer, Falck, Imig et al. Intrarenal CYP-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats. J Hypertens 28, 582-593, 2010.

17. Wang, Hung, Lee et al. Genetic variation in the G-50T polymorphism of the cytochrome P450 epoxygenase CYP2J2 gene and the risk of younger onset type 2 diabetes among Chinese population: potential interaction with body mass index and family history. Exp Clin Endocrinol Diabetes. 118, 346-352, 2010.

18. Cervenka, Hammock, Imig, Kramer et al. Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 300: R1468-R1475. 2011.

19. Xu, Tu, Wang et al. CYP2J3 gene delivery reduces insulin resistance via upregulation of eNos in fructose-treated rats. Cardiovasc Diabetol 10, 114, 2011.

20. Chen, Zeldin, Wang et al. Cytochrome P450 epoxygenase CYP2J2 attenuates nephropathy in streptozotocin-induced diabetic mice. Prostaglandins Other Lipid Mediat 96, 63-71, 2011.

21. Neckar, Kramer, Imig, Hammock, Cervenka et al. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. Clin Sci 122, 513-525, 2012.

22 Zhao, Tu, Wang et al. Delivery of AAV2-CYP2J2 protects remnant kidney in the 5/6-nephrectomized rat via inhibition of apoptosis and fibrosis. Human Gene Therapy 23, 688-699, 2012.

23. Zhao, Cianflone, Zeldin, Wang et al. Epoxyeicosatrienoic acids protect rat hearts against tumor necrosis factor-α-induced injury. J Lipid Res 53, 456-66, 2012.

24. Chen, Xu, Wang et al. Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy. Am J Physiol Endocrinol Metab 303, E563-75, 2012 .

25. Zhang, Xie, Hammock, Zhu et al. Homocysteine upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Circ Res 110, 808-817, 2012.

26. Li R, Xu X , Chen C, Yu X, Edin ML, Degraff LM, Lee CR, Zeldin DC, Wang DW. Cytochrome P450 2J2 is protective against global cerebral ischemia in transgenic mice. Prostaglandins Other Lipid Mediat 99, 68-78, 2012.

27. Cai, Wang et al. CYP2J2 overexpression increases EETs and protects against angiotensin II-induced abdominal aortic aneurysm in mice. J lipid Res 54, 1448-1456, 2013.

28. Xu Tu, Wang et al. CYP2J3 gene delivery up-regulated adiponectin expression via reduced endoplasmic reticulum stress in adipocytes. Endocrinology 154, 1743-53, 2013.

29. Eid, Maalouf, Eid et al. 20-HETE and EETs in diabetic nephropathy: A novel mechanistic pathway. PLOS ONE 8, e70029, 2013.

30. Ma F, Lin F, Chen C, Cheng J, Zeldin DC, Wang Y, Wang DW. Indapamide lowers blood pressure by increasing production of epoxyeicosatrienoic acids in the kidney. Mol Pharmacol 84, 286-295, 2013.

31. Wang, Zhang, Du et al. EETs mediate cardioprotection of salvianolic acids through MAPK signaling pathway. Acta Pharmaceutica Sinica B 3, 25–31, 2013.

32. Xu, Davis, and Hammock et al. A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARγ to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction. International Journal of Cardiology 167, 1298–1304, 2013.

33. Yang, Peng, Xu et al. The role of 14,15-dihydroxyeicosatrienoic acid levels in inflammation and its relationship to lipoproteins. Lipids in Health and Disease 12, 151, 2013.

34. Zhou, Beloiartsev, Bloch et al. Deletion of the Murine Cytochrome P450 Cyp2j Locus by Fused BAC-mediated recombination Identifies a Role for Cyp2j in the Pulmonary Vascular Response to Hypoxia. PLoS Genet. 9, e1003950, 2013.

35. Shen, Peng, Zhao, Xu A potent soluble epoxide hydrolase inhibitor, t-AUCB, modulates cholesterol balance and oxidized low density lipoprotein metabolism in adipocytes in vitro. Biol Chem 395, 443-451 2014.

36. Wang X, Ni L, Yang L, Duan Q, Chen C, Edin ML, Zeldin DC, Wang DW. CYP2J2-derived epoxyeicosatrienoic acids suppress endoplasmic reticulum stress in heart failure. Mol Pharmacol 85, 105-115, 2014.

37. Chen W, Zheng G, Yang S, Ping, W, Fu X, Zhang N, Wang DW, Wang J. CYP2J2 and EETs protect against oxidative stress and apoptosis in vivo and in vitro following lung ischemia/reperfusion. Cell Physiol Biochem, 33, 1663–1680, 2014.

38. Ono E, Dutile S, Kazani S, Wechsler ME, Yang J, Hammock BD, Douda DN, Tabet Y, Khaddaj-Mallat R, Sirois M, Sirois C, Rizcallah E, Rousseau E, Martin R, Sutherland ER, Castro M, N Jarjour N, Israel E, Levy BD and National Heart, Lung, and Blood Institute’s Asthma Clinical Research Network. Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma. Am J Respir Crit Care Med. 15, 190, 886-897, 2014.

39. Kim J, Imig JD, Yang J, Hammock BD, Padanilam BJ. Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation. Am J Physiol Renal Physiol 307, F971-F980, 2014.

40. Sato Y, Sato W, Maruyama S, Wilcox CS, Falck JR, Masuda T, Kosugi T, Kojima H, Maeda K, Furuhashi K, Ando M, Imai E, Matsuo S, Kadomatsu K. Midkine Regulates BP through Cytochrome P450-Derived Eicosanoids. J Am Soc Nephrol. 2015 Aug;26(8):1806-15. doi: 10.1681/ASN.2013121259. PMID: 25377079.

                   41. Li R, Xu X, Chen C, Wang Y, Gruzdev A, Zeldin DC, Wang DW. CYP2J2 attenuates metabolic dysfunction in diabetic mice by reducing hepatic inflammation via the                           PPARγ. Am J Physiol   Endocrinol Metab. 308, E270-E282, 2015

                   42. He Z, Zhang X, Chen C, Wen Z, Hoopes SL, Zeldin DC, Wang DW. Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced                      by angiotensin II.  Cardiovasc Res 105, 304-317, 2015.

43. Tain YL, Huang LT, Chan, JYH, Lee CT. Transcriptome Analysis in rat kidneys: importance of genes involved in programmed hypertension Int J Mol Sci 16, 4744-4758, 2015.

                   44. Chen G, Xu R, Zhang S, Wang Y, Wang P, Edin ML, Zeldin DC, Wang DW. CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet                        in mice. Am J Physiol   Endocrinol Metab. 308, E97-E110, 2015.

45. Dai M, Wu L, He Z, Zhang S, Chen C, Xu X, Wang P, Gruzdev A, Zeldin DC, Wang DW. Epoxyeicosatrienoic Acids Regulate Macrophage Polarization and Prevent LPS-Induced Cardiac Dysfunction. J Cell Physiol. 230(9):2108-19. 2015 doi: 10.1002/jcp.24939. PMID: 25626689.

46. Mattace Raso G, Pirozzi C, d'Emmanuele di Villa Bianca R, Simeoli R, Santoro, A, Lama A, Di Guida F, Russo R, De Caro C, Sorrentino R, Calignano A, Meli R. Palmitoylethanolamide treatment reduces blood pressure in spontaneously hypertensive rats: involvement of cytochrome p450-derived eicosanoids and Renin Angiotensin system. PLoS One. 2015 May 7;10(5):e0123602. doi: 10.1371/journal.pone.0123602. eCollection 2015. PMID: 25951330.

47. Kim J, Yoon SP, Toews ML, Imig JD, Hwang SH, Hammock BD, Padanilam BJ. Pharmacological inhibition of soluble epoxide hydrolase e prevents renal interstitial fibrogenesis in obstructive nephropathy. Am J Physiol Renal Physiol. 2015 Jan 15;308(2):F131-9. doi: 10.1152/ajprenal.00531.2014. PMID: 25377915.

                   48. You WT, Zhou T, Ma ZC, Liang QD, Xiao CR, Tang XL, Tan HL, Zhang BL, Wang YG, Gao Y. Ophiopogonin D maintains Ca(2+) homeostasis in rat cardiomyocytes in                          vitro by upregulating   CYP2J3/EETs and suppressing ER stress. Acta Pharmacol Sin. 2016 Mar;37(3):368-81. doi: 10.1038/aps.2015.146. PMID: 26838069.

49. Santos JM, Joiakim J, Park J-A, Kaplan D, Putt D, Taylor RN, Kim H. Can honokiol be used to ameliorate preeclampsia? Abstract #CV-20, The 16th International Eicosanoid Conference, 2016.

50. Akasaka T, Sueta D, Arima Y, Tabata N, Takasio S, Izumiya Y, Yamamoto E, Tsujita K, Kojima S, Kaikita K, Kajiwara A, Morita K, Oniki K, Saruwatari J, Nakagawa K, Hokimoto S. CYP2C19 variants and epoxy eicosatrienoic acids in patients with microvascular angina. IJC Heart & Vasculature 15:  15-20 (2017).